The Use of Anti-tuberculosis Therapy for Latent TB Infection

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2011 Jun 23

PMID 21694895

Citations 13

Authors

Justin T Denholm

Emma S McBryde

Affiliations

Soon will be listed here.

Abstract

Tuberculosis infection is of global public health significance, with millions of incident cases each year. Many cases, particularly in low-prevalence settings, result from the reactivation of latent tuberculosis infection (LTBI); potentially acquired years prior to active disease. Up to one-third of the world's population has been infected with LTBI, and so may be at risk for future active TB disease. A variety of antituberculosis medications and treatment regimens have now been evaluated in the management of LTBI, with the aim of eradicating tuberculosis bacilli and reducing the likelihood of subsequent reactivation disease. This article reviews LTBI therapies and their use in clinical contexts, and considers future directions for individual and population-based strategies in LTBI management.

Citing Articles

Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment.

Heidary M, Shirani M, Moradi M, Goudarzi M, Pouriran R, Rezaeian T Eur J Microbiol Immunol (Bp). 2022; .

PMID: 35420996 PMC: 9036649. DOI: 10.1556/1886.2021.00021.

Reduced neutrophil granular proteins and post-treatment modulation in tuberculous lymphadenitis.

Kathamuthu G, Moideen K, Sridhar R, Baskaran D, Babu S PLoS One. 2021; 16(6):e0253534.

PMID: 34153068 PMC: 8216526. DOI: 10.1371/journal.pone.0253534.

Association of rs12722 COL5A1 with pulmonary tuberculosis: a preliminary case-control study in a Kazakhstani population.

Zhetkenev S, Khassan A, Khamzina A, Issanov A, Crape B, Akilzhanova A Mol Biol Rep. 2021; 48(1):691-699.

PMID: 33409715 DOI: 10.1007/s11033-020-06121-y.

Detection of DNA in CD34 peripheral blood mononuclear cells of Ugandan adults with latent infection: a cross-sectional and nested prospective study.

Mayito J, Biraro I, Reece S, Martineau A, Kateete D AAS Open Res. 2020; 3:34.

PMID: 32832853 PMC: 7422845. DOI: 10.12688/aasopenres.13108.1.

Active and prospective latent tuberculosis are associated with different metabolomic profiles: clinical potential for the identification of rapid and non-invasive biomarkers.

Albors-Vaquer A, Rizvi A, Matzapetakis M, Lamosa P, Coelho A, Patel A Emerg Microbes Infect. 2020; 9(1):1131-1139.

PMID: 32486916 PMC: 7448900. DOI: 10.1080/22221751.2020.1760734.

References

. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. MMWR Morb Mortal Wkly Rep. 2002; 50(34):733-5. View

Attamna A, Chemtob D, Attamna S, Fraser A, Rorman E, Paul M . Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax. 2009; 64(3):271. DOI: 10.1136/thx.2008.100974. View

Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S . Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006; 43(1):42-6. DOI: 10.1097/01.qai.0000230521.86964.86. View

BYRD R, Horn B, Solomon D, Griggs G . Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA. 1979; 241(12):1239-41. View

Nguyen T, Odermatt P, Slesak G, Barennes H . Risk of latent tuberculosis infection in children living in households with tuberculosis patients: a cross sectional survey in remote northern Lao People's Democratic Republic. BMC Infect Dis. 2009; 9:96. PMC: 2707378. DOI: 10.1186/1471-2334-9-96. View

Villarino M, Ridzon R, Weismuller P, Elcock M, MAXWELL R, Meador J . Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med. 1997; 155(5):1735-8. DOI: 10.1164/ajrccm.155.5.9154885. View

Kritski A, Marques M, Rabahi M, Vieira M, Werneck-Barroso E, Carvalho C . Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996; 153(1):331-5. DOI: 10.1164/ajrccm.153.1.8542139. View

Franks A, Binkin N, Snider Jr D, Rokaw W, Becker S . Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989; 104(2):151-5. PMC: 1580026. View

Tufariello J, Chan J, Flynn J . Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003; 3(9):578-90. DOI: 10.1016/s1473-3099(03)00741-2. View

10.

Burgos M, DeRiemer K, Small P, Hopewell P, Daley C . Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis. 2003; 188(12):1878-84. DOI: 10.1086/379895. View

11.

Saukkonen J, Cohn D, Jasmer R, Schenker S, Jereb J, Nolan C . An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174(8):935-52. DOI: 10.1164/rccm.200510-1666ST. View

12.

Colditz G, Brewer T, Berkey C, Wilson M, Burdick E, Fineberg H . Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271(9):698-702. View

13.

DEVADATTA S, GANGADHARAM P, Andrews R, Fox W, Ramakrishnan C, Selkon J . Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960; 23:587-98. PMC: 2555613. View

14.

Turner J, RHOADES E, Keen M, Belisle J, Frank A, Orme I . Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun. 2000; 68(3):1706-9. PMC: 97334. DOI: 10.1128/IAI.68.3.1706-1709.2000. View

15.

Bernstein J, LOTT W, STEINBERG B, Yale H . Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am Rev Tuberc. 1952; 65(4):357-64. DOI: 10.1164/art.1952.65.4.357. View

16.

Ziakas P, Mylonakis E . 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009; 49(12):1883-9. DOI: 10.1086/647944. View

17.

Narain J, Raviglione M, Kochi A . HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis. 1992; 73(6):311-21. DOI: 10.1016/0962-8479(92)90033-G. View

18.

Gordin F, Chaisson R, Matts J, Miller C, de Lourdes Garcia M, Hafner R . Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American.... JAMA. 2000; 283(11):1445-50. DOI: 10.1001/jama.283.11.1445. View

19.

. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001; 50(15):289-91. View

20.

Lambert P, Hawkridge T, Hanekom W . New vaccines against tuberculosis. Clin Chest Med. 2009; 30(4):811-26, x. DOI: 10.1016/j.ccm.2009.08.014. View